×
About 12,815 results

Risk for Suicide Still Elevated for Individuals With Cancer
https://www.clinicaladvisor.com/home/topics/oncology-information-center/risk-for-suicide-still-elevated-for-individuals-with-cancer/
Clinical Advisor

Jan 20th, 2023 - HealthDay News — Despite a decreasing trend, the risk for suicide is still elevated among individuals with cancer, according to a study published online in JAMA Network Open. Xin Hu, MSPH, from Emory University Rollins School of Public Health in Atlanta, and colleagues conducted a population-based cohort study involving individuals diagnosed with cancer from January 1, 2000, to December 31, 201...

Moderna’s Experimental Cancer Vaccine Treats but Doesn’t Prevent Melanoma – A Biochemist Explains How it Works
https://www.clinicaladvisor.com/home/topics/oncology-information-center/modernas-experimental-cancer-vaccine-treats-doesnt-prevent-melanoma-biochemist-explains-how-it-works/
Clinical Advisor

Jan 17th, 2023 - have reported the encouraging findings of clinical trials for a new experimental vaccine developed by the biotech company to treat an aggressive type of skin cancer called . Although this is potentially very good news, it occurred to me that the headlines may be unintentionally misleading. The vaccines most people are familiar with prevent disease, whereas this experimental new skin cancer vacc...

Many Thyroid Cancer Survivors Cite Inadequate Pretreatment Understanding
https://www.clinicaladvisor.com/home/topics/oncology-information-center/many-thyroid-cancer-survivors-cite-inadequate-pretreatment-understanding/
Clinical Advisor

Jan 2nd, 2023 - HealthDay News — A considerable proportion of survivors of thyroid cancer report inadequate pretreatment understanding, according to a study published online in JAMA Otolaryngology-Head & Neck Surgery. Amanda Silver Karcioglu, MD, from Massachusetts Eye and Ear and Harvard Medical School in Boston, and colleagues administered a cross-sectional survey to members of the ThyCa: Thyroid Survivors’ ...

Screening Catches Only 1 in 7 Cancers
https://www.clinicaladvisor.com/home/topics/oncology-information-center/screening-catches-only-1-in-7-cancers/
Clinical Advisor

Dec 28th, 2022 - HealthDay News — Only 14% of cancers diagnosed in the United States are diagnosed after the patient had a recommended screening test, according to a report released by NORC at the University of Chicago. The percentage of cancers detected by screening (PCDS) in the United States in 2017 was calculated as the product of the screening rate and the expected number of cancers detected per screening,...

Infection-Unrelated Cancers Predominant Among Older Adults With HIV
https://www.clinicaladvisor.com/home/topics/hiv-aids-information-center/infection-unrelated-cancers-predominant-among-older-adults-with-hiv/
Clinical Advisor

Dec 26th, 2022 - Results of a study published in Clinical Infectious Diseases found that rates of infection-unrelated cancers were higher than infection-related cancers among older adults with HIV infection. Data for this study were sourced from the South African HIV Cancer Match (SAM) study, a nationwide cohort conducted among individuals with HIV infection. Using data collected between 2004 and 2014, infectio...

Long-Term Data Reinforce Targeted Combo Versus Single Agent for Advanced Melanoma
https://www.medpagetoday.com/hematologyoncology/skincancer/102302

Dec 19th, 2022 - Combination targeted therapy significantly improved 5-year progression-free survival (PFS) and overall survival (OS) versus single-agent vemurafenib (Zelboraf) and was numerically superior to single-agent encorafenib (Braftovi), long-term follow-up from a randomized trial confirmed. Encorafenib plus binimetinib (Mektovi) led to 5-year PFS and OS rates of 23% and 35%, including rates of 31% and ...

Breast Cancer: a Diagnosis That Extends Beyond the Patient
https://www.clinicaladvisor.com/home/topics/oncology-information-center/breast-cancer-diagnosis-genetic-testing/
Clinical Advisor

Dec 12th, 2022 - A well-appearing 35-year-old woman presents to her primary care provider with a complaint of a mass in her left breast. She has no significant medical history; however, her mother has had recurrent breast cancer. The patient had one pregnancy with an uncomplicated vaginal delivery at age 30. Her daughter was breastfed for 8 months. The patient’s age at menarche was 11 years old. She has never h...

Mindfulness Program Reduces Burnout, Compassion Fatigue in Nurses
https://www.clinicaladvisor.com/home/topics/oncology-information-center/nurse-mindfulness-program-reduces-burnout-compassion-fatigue-risk/
Clinical Advisor

Dec 2nd, 2022 - A mindfulness-based stress reduction (MBSR) intervention for nurses working in pediatric oncology lowered compassion fatigue and burnout. These findings were presented at a European Nursing Society (EONS) session at the European Society for Medical Oncology (ESMO) Congress. Pediatric hematology-oncology nurses are frequently exposed to the pain or distressing situations experienced by the child...

Top Recent FDA Approvals
https://www.clinicaladvisor.com/home/topics/practice-management-information-center/top-recent-fda-approvals/
Clinical Advisor

Dec 1st, 2022 - The US Food and Drug Administration (FDA) approved several drugs relevant to conditions often treated by nurse practitioners and PAs. Approvals include treatments for hemophilia B, acute low back pain, postoperative nausea and vomiting, multiple myeloma, and fibromyalgia pain. Gene Therapy for Hemophilia B The first gene therapy for adults with hemophilia B (congential Factor IX deficiency) has...

Building the Optimal Patient Experience Takes Planning and Effort
https://www.onclive.com/view/building-the-optimal-patient-experience-takes-planning-and-effort

Nov 22nd, 2022 - Although cancer is the second leading cause of death in the United States, unprecedented progress in treatment has been made in recent years.1 Precision oncology, artificial intelligence, breakthroughs in drug therapy, new digital health applications, and advanced detection strategies have revolutionized the field and significantly improved prognosis. There is, however, another factor that play...

USPSTF: Evidence Still Lacking for Routine Skin Cancer Screening
https://www.clinicaladvisor.com/home/topics/dermatology-information-center/uspstf-evidence-still-lacking-routine-skin-cancer-screening/
Clinical Advisor

Oct 26th, 2022 - HealthDay News — The US Preventive Services Task Force (USPSTF) concludes that the evidence is currently insufficient for assessing the balance of benefits and harms of screening asymptomatic adolescents and adults for skin cancer. These findings form the basis of a draft recommendation statement published online October 25 by the USPSTF. Nora B. Henrikson, PhD, MPH, from the Kaiser Permanente ...

Trial Raises Questions About Effectiveness of Colonoscopy for Colorectal Cancer Screening
https://www.clinicaladvisor.com/home/topics/oncology-information-center/colorectal-cancer-screening-nordicc-trial-question-effectiveness/
Clinical Advisor

Oct 24th, 2022 - New research casts doubt on the effectiveness of screening colonoscopy for preventing colorectal cancer (CRC) and CRC-related death.1 The study showed that patients assigned to undergo screening colonoscopy had an 18% reduction in the risk of CRC over a period of 10 years, but these patients had no significant reduction in the risk of CRC-related death, compared with patients not assigned to sc...

Black Women Have Less Access to Newer Mammogram Technology
https://www.clinicaladvisor.com/home/topics/oncology-information-center/black-women-have-less-access-newer-mammogram-technology/
Clinical Advisor

Oct 18th, 2022 - HealthDay News — From 2005 to 2020, Black women had less access to new mammographic imaging technology compared with White women in the Medicare population, according to a study published online in Radiology. Eric W. Christensen, PhD, from the Neiman Health Policy Institute in Reston, Virginia, and colleagues examined the relationship between use of newer mammographic technology and race in wom...

Enlarging Breast Mass in 69-Year-Old Woman With History of Cysts
https://www.clinicaladvisor.com/home/topics/oncology-information-center/breast-mass-in-woman/
Clinical Advisor

Oct 14th, 2022 - A 69-year-old woman presents to the clinic with complaints of a large right breast mass that has grown rapidly over the past 2 weeks. The patient reports she was in the shower conducting a routine breast self-examination when she noticed a firm, nontender, moveable hard mass. She states there was no nipple discharge. The mass has greatly increased in size since first being felt just a couple of...

Neoadjuvant Nivolumab-Ipilimumab Could Be New Standard Care in dMMR Colon Cancer
https://www.clinicaladvisor.com/home/topics/oncology-information-center/neoadjuvant-nivolumab-ipilimumab-standard-care-dmmr-colon-cancer-niche-2/
Clinical Advisor

Oct 5th, 2022 - Neoadjuvant nivolumab plus ipilimumab could be a new standard of care for patients with mismatch repair-deficient (dMMR) colon cancer, according to a presentation at ESMO Congress 2022. The combination was well tolerated and produced an “unprecedented” major pathologic response rate in the NICHE-2 study, according to study presenter Myriam Chalabi, MD, PhD, of the Netherlands Cancer Institute i...

Immunotherapy First for BRAF Melanoma Edges Out Targeted Combination
https://www.medpagetoday.com/hematologyoncology/skincancer/100958

Sep 28th, 2022 - First-line immunotherapy for BRAF-positive melanoma, followed by targeted therapy at progression, led to a "clinically meaningful" survival benefit, a randomized trial showed. Combination immunotherapy with nivolumab (Opdivo) and ipilimumab (Yervoy) as initial treatment led to 2- and 3-year overall survival (OS) of 73% and 62% whereas two different strategies of first-line targeted therapy were...

Effects of Breast Cancer Treatments on Cardiovascular Disease Risk Factors
https://www.clinicaladvisor.com/home/topics/oncology-information-center/breast-cancer-treatments-cardiovascular-disease/
Clinical Advisor

Sep 21st, 2022 - The survival rate of women with breast cancer has been steadily increasing each year since 2007. The 5-year survival rate for women with nonmetastatic invasive breast cancer is currently 90%.1 As survival rates have increased, studies have demonstrated that rates of cardiovascular disease in the same population have been increasing as well. This is an important observation, as cardiovascular di...

Multimodal Treatment Linked to 3-Year Overall Survival in Esophageal Cancer
https://www.clinicaladvisor.com/home/topics/gastroenterology-information-center/multimodal-treatment-linked-to-3-year-overall-survival-in-esophageal-cancer/
Clinical Advisor

Sep 20th, 2022 - Multimodality treatment, including a surgical procedure, may be associated with 3-year overall survival in patients with metastatic esophageal cancer, according to a study in Cancers. Researchers conducted a systematic review of published studies on surgical procedures in patients with synchronous metastatic esophageal cancer to assess the long-term outcomes of multimodal treatments. Researcher...

Incidence of Cutaneous T-Cell Lymphoma Up in the US
https://www.clinicaladvisor.com/home/topics/oncology-information-center/incidence-cutaneous-t-cell-lymphoma-up-us/
Clinical Advisor

Sep 13th, 2022 - HealthDay News — The overall incidence of cutaneous T-cell lymphoma (CTCL) increased in the United States from 2000 to 2018, according to a research letter published online in JAMA Oncology. Zhuo Ran Cai, MD, from Stanford University in California, and colleagues describe recent trends in the incidence of histologically confirmed cases of first primary CTCL with malignant behavior and skin as t...

FDA Warns of Rare Cases of Certain Cancers Linked to Breast Implants
https://www.clinicaladvisor.com/home/topics/oncology-information-center/fda-warns-rare-cases-certain-cancers-linked-breast-implants/
Clinical Advisor

Sep 12th, 2022 - HealthDay News — The US Food and Drug Administration on Thursday warned doctors and their patients about rare cases of squamous cell carcinoma and various lymphomas developing in the scar tissue that forms around breast implants. These cancers are different from an earlier FDA warning about . Federal regulators discovered reports of the cancers as part of a routine postmarket review and caution...